Patents Assigned to Board of Supervisors of Louisiana University and Agricultural
and Mechanical College
-
Patent number: 6442663Abstract: A technique for process migration between computers is disclosed, particularly for collecting the memory contents of a process on one computer in a machine-independent information stream, and for restoring the data content from the information stream to the memory space of a new process on a different computer. The data collection and restoration method enables sophisticated data structures such as indirect memory references to be migrated appropriately between heterogeneous computer environments.Type: GrantFiled: June 19, 1998Date of Patent: August 27, 2002Assignee: Board of Supervisors of Louisiana University and Agricultural and Mechanical CollegeInventors: Xian-He Sun, Kasidit Chanchio
-
Patent number: 5872133Abstract: Methods for upregulating abnormal responses of the mammalian immune system are provided. Also disclosed are methods for modifying normal responses of the mammalian immune system. Further disclosed is a method for administering to a mammal a prolactin reducer and/or enhancer at a pre-determined time or times during a 24-hour period that results in modification of the mammal's abnormal prolactin profile so that it approaches or conforms to the prolactin profile of a young, healthy mammal of the same species (or to a standard profile generated from such individuals).Type: GrantFiled: June 2, 1995Date of Patent: February 16, 1999Assignees: The Board of Supervisors of Louisiana University and Agricultural and Mechanical College, The General Hospital CorporationInventors: Anthony H. Cincotta, Albert H. Meier
-
Patent number: 5750519Abstract: A process for the long term modification and regulation of lipid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, or Type II diabetes)--by administration to a vertebrate, animal or human, of a dopamine agonist and a prolactin stimulator. The dopamine agonist and prolactin stimulator are administered in daily dosages, respectively, at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases in body fat deposits result by treatment of an obese species on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean insulin sensitive members of a similar species. The dopamine agonist is administered at the time of.Type: GrantFiled: October 31, 1995Date of Patent: May 12, 1998Assignees: The Board of Supervisors of Louisiana University and Agricultural and Mechanical College, Ergo Research CorporationInventors: Anthony H. Cincotta, Albert H. Meier
-
Patent number: 5700800Abstract: A process for the long term modification and regulation of lipid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, or Type II diabetes)--by administration to a vertebrate, animal or human, of a dopamine agonist and a prolactin stimulator. The dopamine agonist and prolactin stimulator are administered in daily dosages, respectively, at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases in body fat deposits result by treatment of an obese species on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean insulin sensitive members of a similar species.Type: GrantFiled: October 31, 1995Date of Patent: December 23, 1997Assignees: Ergo Science Incorporated, The Board of Supervisors of Louisiana University and Agricultural and Mechanical CollegeInventors: Anthony H. Cincotta, Albert H. Meier
-
Patent number: 5696128Abstract: Disclosed are methods for rectifying or ameliorating abnormal responses of mammalian immune systems. Also disclosed are methods for modifying normal responses of the mammalian immune system. Further disclosed are methods for accomplishing the foregoing by administering to a mammal a prolactin reducer and/or enhancer at a pre-determined time or times during a 24-hour period that results in modification of the mammal's abnormal prolactin profile so that it approaches or conforms to the prolactin profile of a young, healthy mammal of the same species (or to a standard profile generated from such individuals). Additionally, methods of upregulating or augmenting an immune response in a mammal are disclosed.Type: GrantFiled: July 7, 1994Date of Patent: December 9, 1997Assignees: The Board of Supervisors of Louisiana University and Agricultural and Mechanical College, The General Hospital CorporationInventors: Anthony H. Cincotta, Albert H. Meier
-
Patent number: 5665375Abstract: A method for reducing the total fat and cholesterol contents and the ratio of saturated to unsaturated fatty acids and for increasing total protein content in eggs produced by animals is described. The level of n-Dihydroxyphenylalanine (L-DOPA) in the bloodstream of the poultry is elevated so as to cause the animals to produce eggs which have a reduced cholesterol content and eggs which have a lower ratio of saturated to unsaturated fatty acids. In a preferred embodiment the L-DOPA is orally administered to poultry by incorporation in the food for said poultry.Type: GrantFiled: May 31, 1995Date of Patent: September 9, 1997Assignee: Board of Supervisors of Louisiana University and Agricultural and Mechanical CollegeInventors: Albert H. Meier, John M. Wilson
-
Patent number: 5654313Abstract: A process for the long term modification and regulation of lipid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, or Type II diabetes)--by administration to a vertebrate, animal or human, of a dopamine agonist and a prolactin stimulator. The dopamine agonist and prolactin stimulator are administered in daily dosages, respectively, at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases in body fat deposits result by treatment of an obese species on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean insulin sensitive members of a similar species.Type: GrantFiled: June 6, 1995Date of Patent: August 5, 1997Assignees: Ergo Science Incorporated, Board of Supervisors of Louisiana University and Agricultural and Mechanical CollegeInventors: Anthony H. Cincotta, Albert H. Meier
-
Patent number: 5650438Abstract: A process is provided for activating reproduction in seasonal breeding vertebrates during normally non-reproductive seasons by administering L-dihydroxyphenylalanine (L-DOPA), thereby increasing the level of L-DOPA in the vertebrate's bloodstream to a reproductively active level. An effective amount of 5-HTP can also be injected into the vertebrate followed, an effective period of time later, with an injection of an effective amount of L-DOPA.Type: GrantFiled: June 5, 1995Date of Patent: July 22, 1997Assignee: The Board of Supervisors of Louisiana University and Agricultural and Mechanical CollegeInventors: Albert H. Meier, John M. Wilson
-
Patent number: 5554623Abstract: A process for the long term modification and regulation of lipid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, or Type II diabetes)--by administration to a vertebrate, animal or human, of a dopamine agonist and a prolactin stimulator. The dopamine agonist and prolactin stimulator are administered in daily dosages, respectively, at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases in body fat deposits result by treatment of an obese species on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean insulin sensitive members of a similar species.Type: GrantFiled: May 26, 1994Date of Patent: September 10, 1996Assignees: Ergo Science Incorporated, The Board of Supervisors of Louisiana University and Agricultural and Mechanical CollegeInventors: Anthony H. Cincotta, Albert H. Meier
-
Patent number: 5344832Abstract: A process for the long term modification and regulation of lipid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, or Type II diabetes)--by administration to a vertebrate, animal or human, of a dopamine agonist and a prolactin stimulator. The dopamine agonist and prolactin stimulator are administered in daily dosages, respectively, at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases in body fat deposits result by treatment of an obese species on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean insulin sensitive members of a similar species.Type: GrantFiled: June 24, 1991Date of Patent: September 6, 1994Assignees: The Board of Supervisors of Louisiana University and Agricultural and Mechanical College, Ergo Science IncorporatedInventors: Anthony H. Cincotta, Albert H. Meier